Beam Therapeutics Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Beam Therapeutics reported Q2 2026 results with $1.2B in cash (flat vs. Dec 2025) and added $200M credit facility access, extending runway to mid-2029. Key progress: first patient dosed in BEAM-302 pivotal cohort (AATD); completed dosing in risto-cel BEACON trial (SCD) with BLA expected by year-end 2026; FDA cleared IND for BEAM-304 (PKU). Q2 net loss was $122.7M ($1.18/share) vs. $102.1M year-ago; R&D $95.1M, G&A $31.9M.
Why this rating
Pivotal cohort initiation and BLA path are material program advances, but cash position stable relative to $1.7B market cap; runway adequate through catalysts.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.